Status:
ENROLLING_BY_INVITATION
Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
Lead Sponsor:
CSL Behring
Conditions:
Hemophilia B
Eligibility:
MALE
18+ years
Brief Summary
The primary purpose of this study is to assess the long-term safety and efficacy in male adults with hemophilia B who were treated with CSL222 (CSL222) in parent studies CSL222\_2001 (NCT03489291) or ...
Eligibility Criteria
Inclusion
- Received treatment with CSL222 in Study CSL222\_2001 or Study CSL222\_3001, and completed participation in Study CSL222\_2001 or Study CSL222\_3001 or at least 5 years have passed since receiving CSL222.
Exclusion
- Not Applicable
Key Trial Info
Start Date :
August 30 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 23 2035
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT05962398
Start Date
August 30 2023
End Date
March 23 2035
Last Update
July 18 2025
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
10-15 Phoenix Childrens Hospital
Phoenix, Arizona, United States, 85016
2
10-14 Arkansas Children's Hospital - Pharmacology
Little Rock, Arkansas, United States, 72202
3
10-22 Orthopaedic Institute for Children
Los Angeles, California, United States, 90007
4
10-21 Children's Hospital of Los Angeles
Los Angeles, California, United States, 90027